The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
1 Report Overview 1.1 Study Scope and Definition 1.2 Research Methodology 1.2.1 Methodology/Research Approach 1.2.2 Data Source 1.3 Key Market Segments 1.4 Players Covered: Ranking by Urological Cancer Therapeutics Drugs Revenue 1.5 Market Analysis by Type 1.5.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type: 2020 VS 2026 1.5.2 Xofigo (radium Ra 223 dichloride) 1.5.3 Jevtana (cabazitaxel) 1.5.4 Inlyta (axitinib) 1.5.5 Votrient (pazopanib hydrochloride) 1.5.6 Sutent (sunitinib malate) 1.5.7 Zytiga (abiraterone acetate) 1.5.8 Xtandi (enzalutamide) 1.5.9 Opdivo (nivolumab) 1.5.10 Provenge (sipuleucel-T) 1.6 Market by Application 1.6.1 Global Urological Cancer Therapeutics Drugs Market Share by Application: 2021-2026 1.6.2 Hospital 1.6.3 Medical Research Laboratory 1.6.4 Others 1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 1.7.2 Covid-19 Impact: Commodity Prices Indices 1.7.3 Covid-19 Impact: Global Major Government Policy 1.8 Study Objectives 1.9 Years Considered 2 Global Urological Cancer Therapeutics Drugs Market Trends and Growth Strategy 2.1 Market Top Trends 2.2 Market Drivers 2.3 Market Challenges 2.4 Porter's Five Forces Analysis 2.5 Market Growth Strategy 2.6 SWOT Analysis 3 Global Urological Cancer Therapeutics Drugs Market Players Profiles 3.1 Novartis 3.1.1 Novartis Company Profile 3.1.2 Novartis Urological Cancer Therapeutics Drugs Product Specification 3.1.3 Novartis Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.2 Celgene Corporation 3.2.1 Celgene Corporation Company Profile 3.2.2 Celgene Corporation Urological Cancer Therapeutics Drugs Product Specification 3.2.3 Celgene Corporation Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.3 AstraZeneca 3.3.1 AstraZeneca Company Profile 3.3.2 AstraZeneca Urological Cancer Therapeutics Drugs Product Specification 3.3.3 AstraZeneca Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.4 Pfizer 3.4.1 Pfizer Company Profile 3.4.2 Pfizer Urological Cancer Therapeutics Drugs Product Specification 3.4.3 Pfizer Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.5 Abbott Laboratories 3.5.1 Abbott Laboratories Company Profile 3.5.2 Abbott Laboratories Urological Cancer Therapeutics Drugs Product Specification 3.5.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.6 Johnson & Johnson 3.6.1 Johnson & Johnson Company Profile 3.6.2 Johnson & Johnson Urological Cancer Therapeutics Drugs Product Specification 3.6.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.7 Ferring Pharmaceuticals 3.7.1 Ferring Pharmaceuticals Company Profile 3.7.2 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Specification 3.7.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.8 Bristol-Myers Squibb 3.8.1 Bristol-Myers Squibb Company Profile 3.8.2 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Specification 3.8.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.9 Astellas 3.9.1 Astellas Company Profile 3.9.2 Astellas Urological Cancer Therapeutics Drugs Product Specification 3.9.3 Astellas Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.10 Dendreon Corporation 3.10.1 Dendreon Corporation Company Profile 3.10.2 Dendreon Corporation Urological Cancer Therapeutics Drugs Product Specification 3.10.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.11 Sanofi S.A. 3.11.1 Sanofi S.A. Company Profile 3.11.2 Sanofi S.A. Urological Cancer Therapeutics Drugs Product Specification 3.11.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.12 GlaxoSmithKline plc 3.12.1 GlaxoSmithKline plc Company Profile 3.12.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Specification 3.12.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.13 Roche Healthcare 3.13.1 Roche Healthcare Company Profile 3.13.2 Roche Healthcare Urological Cancer Therapeutics Drugs Product Specification 3.13.3 Roche Healthcare Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.14 Indevus Pharmaceuticals Inc 3.14.1 Indevus Pharmaceuticals Inc Company Profile 3.14.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Specification 3.14.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.15 Ipsen 3.15.1 Ipsen Company Profile 3.15.2 Ipsen Urological Cancer Therapeutics Drugs Product Specification 3.15.3 Ipsen Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020) 4 Global Urological Cancer Therapeutics Drugs Market Competition by Market Players 4.1 Global Urological Cancer Therapeutics Drugs Production Capacity Market Share by Market Players (2015-2020) 4.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Market Players (2015-2020) 4.3 Global Urological Cancer Therapeutics Drugs Average Price by Market Players (2015-2020) 5 Global Urological Cancer Therapeutics Drugs Production by Regions (2015-2020) 5.1 North America 5.1.1 North America Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.1.2 Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020) 5.1.3 North America Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.1.4 North America Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.2 East Asia 5.2.1 East Asia Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.2.2 Urological Cancer Therapeutics Drugs Key Players in East Asia (2015-2020) 5.2.3 East Asia Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.2.4 East Asia Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.3 Europe 5.3.1 Europe Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.3.2 Urological Cancer Therapeutics Drugs Key Players in Europe (2015-2020) 5.3.3 Europe Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.3.4 Europe Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.4 South Asia 5.4.1 South Asia Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.4.2 Urological Cancer Therapeutics Drugs Key Players in South Asia (2015-2020) 5.4.3 South Asia Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.4.4 South Asia Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.5 Southeast Asia 5.5.1 Southeast Asia Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.5.2 Urological Cancer Therapeutics Drugs Key Players in Southeast Asia (2015-2020) 5.5.3 Southeast Asia Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.5.4 Southeast Asia Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.6 Middle East 5.6.1 Middle East Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.6.2 Urological Cancer Therapeutics Drugs Key Players in Middle East (2015-2020) 5.6.3 Middle East Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.6.4 Middle East Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.7 Africa 5.7.1 Africa Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.7.2 Urological Cancer Therapeutics Drugs Key Players in Africa (2015-2020) 5.7.3 Africa Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.7.4 Africa Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.8 Oceania 5.8.1 Oceania Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.8.2 Urological Cancer Therapeutics Drugs Key Players in Oceania (2015-2020) 5.8.3 Oceania Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.8.4 Oceania Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.9 South America 5.9.1 South America Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.9.2 Urological Cancer Therapeutics Drugs Key Players in South America (2015-2020) 5.9.3 South America Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.9.4 South America Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 5.10 Rest of the World 5.10.1 Rest of the World Urological Cancer Therapeutics Drugs Market Size (2015-2020) 5.10.2 Urological Cancer Therapeutics Drugs Key Players in Rest of the World (2015-2020) 5.10.3 Rest of the World Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020) 5.10.4 Rest of the World Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020) 6 Global Urological Cancer Therapeutics Drugs Consumption by Region (2015-2020) 6.1 North America 6.1.1 North America Urological Cancer Therapeutics Drugs Consumption by Countries 6.1.2 United States 6.1.3 Canada 6.1.4 Mexico 6.2 East Asia 6.2.1 East Asia Urological Cancer Therapeutics Drugs Consumption by Countries 6.2.2 China 6.2.3 Japan 6.2.4 South Korea 6.3 Europe 6.3.1 Europe Urological Cancer Therapeutics Drugs Consumption by Countries 6.3.2 Germany 6.3.3 United Kingdom 6.3.4 France 6.3.5 Italy 6.3.6 Russia 6.3.7 Spain 6.3.8 Netherlands 6.3.9 Switzerland 6.3.10 Poland 6.4 South Asia 6.4.1 South Asia Urological Cancer Therapeutics Drugs Consumption by Countries 6.4.2 India 6.5 Southeast Asia 6.5.1 Southeast Asia Urological Cancer Therapeutics Drugs Consumption by Countries 6.5.2 Indonesia 6.5.3 Thailand 6.5.4 Singapore 6.5.5 Malaysia 6.5.6 Philippines 6.6 Middle East 6.6.1 Middle East Urological Cancer Therapeutics Drugs Consumption by Countries 6.6.2 Turkey 6.6.3 Saudi Arabia 6.6.4 Iran 6.6.5 United Arab Emirates 6.7 Africa 6.7.1 Africa Urological Cancer Therapeutics Drugs Consumption by Countries 6.7.2 Nigeria 6.7.3 South Africa 6.8 Oceania 6.8.1 Oceania Urological Cancer Therapeutics Drugs Consumption by Countries 6.8.2 Australia 6.9 South America 6.9.1 South America Urological Cancer Therapeutics Drugs Consumption by Countries 6.9.2 Brazil 6.9.3 Argentina 6.10 Rest of the World 6.10.1 Rest of the World Urological Cancer Therapeutics Drugs Consumption by Countries 7 Global Urological Cancer Therapeutics Drugs Production Forecast by Regions (2021-2026) 7.1 Global Forecasted Production of Urological Cancer Therapeutics Drugs (2021-2026) 7.2 Global Forecasted Revenue of Urological Cancer Therapeutics Drugs (2021-2026) 7.3 Global Forecasted Price of Urological Cancer Therapeutics Drugs (2021-2026) 7.4 Global Forecasted Production of Urological Cancer Therapeutics Drugs by Region (2021-2026) 7.4.1 North America Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.2 East Asia Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.3 Europe Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.4 South Asia Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.5 Southeast Asia Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.6 Middle East Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.7 Africa Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.8 Oceania Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.9 South America Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.4.10 Rest of the World Urological Cancer Therapeutics Drugs Production, Revenue Forecast (2021-2026) 7.5 Forecast by Type and by Application (2021-2026) 7.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026) 7.5.2 Global Forecasted Consumption of Urological Cancer Therapeutics Drugs by Application (2021-2026) 8 Global Urological Cancer Therapeutics Drugs Consumption Forecast by Regions (2021-2026) 8.1 North America Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 8.2 East Asia Market Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 8.3 Europe Market Forecasted Consumption of Urological Cancer Therapeutics Drugs by Countriy 8.4 South Asia Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 8.5 Southeast Asia Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 8.6 Middle East Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 8.7 Africa Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 8.8 Oceania Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 8.9 South America Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 8.10 Rest of the world Forecasted Consumption of Urological Cancer Therapeutics Drugs by Country 9 Global Urological Cancer Therapeutics Drugs Sales by Type (2015-2026) 9.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Type (2015-2020) 9.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2021-2026) 10 Global Urological Cancer Therapeutics Drugs Consumption by Application (2015-2026) 10.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Application (2015-2020) 10.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2021-2026) 11 Global Urological Cancer Therapeutics Drugs Manufacturing Cost Analysis 11.1 Urological Cancer Therapeutics Drugs Key Raw Materials Analysis 11.1.1 Key Raw Materials 11.2 Proportion of Manufacturing Cost Structure 11.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs 12 Global Urological Cancer Therapeutics Drugs Marketing Channel, Distributors, Customers and Supply Chain 12.1 Marketing Channel 12.2 Urological Cancer Therapeutics Drugs Distributors List 12.3 Urological Cancer Therapeutics Drugs Customers 12.4 Urological Cancer Therapeutics Drugs Supply Chain Analysis 13 Analyst's Viewpoints/Conclusions 14 Disclaimer
Price : US$ 2,450 | Date : Feb 2024 |
Category : Healthcare and Pharmaceuticals | Pages : 221 |
Price : US$ 2,450 | Date : Feb 2024 |
Category : Healthcare and Pharmaceuticals | Pages : 260 |
Price : US$ 3,500 | Date : Jan 2024 |
Category : Healthcare and Pharmaceuticals | Pages : 143 |
Price : US$ 3,500 | Date : Jan 2024 |
Category : Medical Devices | Pages : 123 |
Price : US$ 3,500 | Date : Jan 2024 |
Category : Healthcare and Pharmaceuticals | Pages : 117 |
We will be happy to help you find what you need. Please call us or write to us: